Lupin Pharmaceuticals, Inc., the US-based wholly-owned subsidiary of India-based global pharma major Lupin Limited, announced on Wednesday that it has introduced Tiotropium Bromide Inhalation Powder, 18mcg/capsule intended for the treatment of chronic obstructive pulmonary disease (COPD) in the US.

The product, a generic equivalent of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder), 18mcg/capsule from Boehringer Ingelheim Pharmaceuticals, Inc., offers an alternative to combat COPD.

Vinita Gupta, Lupin CEO, said, 'We are delighted to announce the launch of generic Spiriva HandiHaler in the US, the first generic to this important drug for COPD. This launch is a testament to our commitment to advancing healthcare accessibility and is a result of years of hard work and dedication to building our complex products and respiratory franchise. Being the first to bring an FDA-approved generic version of Spiriva in the US further reaffirms our commitment to enhancing the well-being of COPD patients for a healthier future.'